07:00 , Oct 30, 2008 |  BC Innovations  |  Tools & Techniques

Expanding the kinase kingdom

Researchers at Harvard Medical School , the Dana-Farber Cancer Institute and Brigham and Women's Hospital have applied loss-of-function small hairpin RNA screens to various human cell lines to identify kinases that are essential for cell...
07:00 , Jul 30, 2007 |  BioCentury  |  Regulation

GPC chronicles

GPC chronicles GPC (FSE:GPC; GPCB), which was founded in 1997, originally was a genomics- and proteomics-based drug discovery company focused on oncology, infectious diseases and immunology. Since it in-licensed Orplatna satraplatin in 2002, its focus...
08:00 , Jan 23, 2006 |  BioCentury  |  Finance

In and out at Novartis Venture

In and out at Novartis Venture In and out at Novartis Venture Novartis Venture Fund last week released its report card for 2005. The firm saw its portfolio shrink to 62 private companies (61 assuming...
07:00 , May 23, 2005 |  BioCentury  |  Finance

Europe's Iceberg 2005

Europe's first generation of biotech companies failed to yield a critical mass of bellwethers with market caps above $1 billion. Now that the next generation is in the clinic, with at least 129 companies with...
08:00 , Mar 14, 2005 |  BioCentury  |  Strategy

Burn free discovery

Oncology company GPC Biotech AG has expanded over the years via asset accumulation. This month's addition of key assets from bankrupt kinase play Axxima Pharmaceuticals AG is in line with that strategy. Founded in 1997...
08:00 , Mar 7, 2005 |  BC Week In Review  |  Company News

Axxima, GPC Biotech deal

Cancer company, GPC, acquired the assets of kinase discovery company Axxima (Munich, Germany) for E13.7 million ($18.1 million) in stock. GPC will issue 1.3 million shares at E10.47 ($13.87), which is a 7% premium to...
08:00 , Mar 7, 2005 |  BioCentury  |  Finance

Ebb & Flow

Aspreva's IPO on Thursday evening and subsequent stock pop on Friday suggest that many investors are willing to treat the suspension of multiple sclerosis drug Tysabri as a company-specific event. Indeed, the IPO was a...
03:33 , Mar 3, 2005 |  BC Extra  |  Company News

GPC acquires Axxima's assets

Cancer company GPC Biotech (FSE:GPC; GPCB) acquired the assets of kinase discovery company Axxima (Munich, Germany) for EUR 13.7 million ($18.1 million) in stock. GPC will issue 1.3 million shares at EUR 10.47 ($13.87), which...
08:00 , Jan 10, 2005 |  BC Extra  |  Company News

Three German insolvencies

Infectious disease company Axxima and antibody play Xerion filed for insolvency. Each company is now being advised by a court-appointed insolvency manager who will determine whether to open insolvency proceedings or to continue operations. Axxima...
07:00 , Jun 29, 2004 |  BC Extra  |  Financial News

Axxima raises EUR 10 million

Axxima (Munich, Germany) raised EUR 10 million ($12.2 million) in a venture round led by TVM Techno Venture Management. The infectious disease and cancer company has raised a total of EUR 64 million since it...